HRP20050214B1 - Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti - Google Patents

Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti

Info

Publication number
HRP20050214B1
HRP20050214B1 HRP20050214AA HRP20050214A HRP20050214B1 HR P20050214 B1 HRP20050214 B1 HR P20050214B1 HR P20050214A A HRP20050214A A HR P20050214AA HR P20050214 A HRP20050214 A HR P20050214A HR P20050214 B1 HRP20050214 B1 HR P20050214B1
Authority
HR
Croatia
Prior art keywords
oral solid
solid drug
crystal
treatment containing
dysuria
Prior art date
Application number
HRP20050214AA
Other languages
English (en)
Inventor
Eiji Tsuru
Michio Toda
Kazuma Hirata
Original Assignee
Kissei Pharmaceutical Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31973150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050214(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Co.Ltd. filed Critical Kissei Pharmaceutical Co.Ltd.
Publication of HRP20050214A2 publication Critical patent/HRP20050214A2/hr
Publication of HRP20050214B1 publication Critical patent/HRP20050214B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Kristal za čvrsti oralni lijek koji sadržava indolin spoj (KMD-3213) koji ima blokirajući učinak na ai-adrenalin receptor, može se koristiti kao terapijsko sredstvo za disuriju i predstavljeno je formulom: (I) koje je powder X-ray difrakcijom pattern, okarakterizirano s glavnim pikovima od od 5.5°+0.2°, 6.1°±0.2°, 9.8°+0.2°, 11.1°±0.2°, 12.2°+0.2, 16.4°±0.2°, 19.7°±0.2° i 20.0°±0.2° kao 20. Nadalje je osiguran čvrsti oralni lijek za tretiranje disurije koji sadržava kristal kao aktivni sastojak.
HRP20050214AA 2002-09-06 2005-03-04 Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti HRP20050214B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002262157 2002-09-06
PCT/JP2003/011345 WO2004022538A1 (ja) 2002-09-06 2003-09-05 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬

Publications (2)

Publication Number Publication Date
HRP20050214A2 HRP20050214A2 (en) 2006-05-31
HRP20050214B1 true HRP20050214B1 (hr) 2013-09-30

Family

ID=31973150

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050214AA HRP20050214B1 (hr) 2002-09-06 2005-03-04 Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti

Country Status (24)

Country Link
US (1) US20060142374A1 (hr)
EP (1) EP1541554B1 (hr)
JP (1) JP4532274B2 (hr)
KR (1) KR100670592B1 (hr)
CN (1) CN1321111C (hr)
AT (1) ATE416159T1 (hr)
AU (1) AU2003264385B2 (hr)
BR (1) BR0314338A (hr)
CA (1) CA2496780C (hr)
DE (1) DE60325074D1 (hr)
ES (1) ES2316858T3 (hr)
HK (1) HK1084396A1 (hr)
HR (1) HRP20050214B1 (hr)
IL (1) IL167168A (hr)
IS (1) IS2640B (hr)
MX (1) MXPA05002549A (hr)
NO (2) NO329855B1 (hr)
NZ (1) NZ538598A (hr)
PL (1) PL375701A1 (hr)
RU (1) RU2347774C2 (hr)
TW (1) TW200407126A (hr)
UA (1) UA78854C2 (hr)
WO (1) WO2004022538A1 (hr)
ZA (1) ZA200501884B (hr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317349A (pt) * 2002-12-16 2005-11-16 Kissei Pharmaceutical Droga sólida para uso oral
CN1930123B (zh) * 2004-03-05 2010-06-23 橘生药品工业株式会社 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
EP1800677A4 (en) * 2004-10-05 2008-04-02 Kissei Pharmaceutical AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF URINE COLLECTION DISORDERS IN BLADDER OF THE BLADDER OF THE LOWER URINARY CANAL
ATE535242T1 (de) * 2004-10-06 2011-12-15 Kissei Pharmaceutical Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
EP1838326A4 (en) * 2005-02-02 2009-09-30 Teva Pharma PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
WO2008106125A2 (en) * 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
ES2471076T3 (es) 2010-06-28 2014-06-25 Ratiopharm Gmbh Compuestos de inclusión de silodoxina-ciclodextrina
JP2013532651A (ja) 2010-07-23 2013-08-19 ラティオファルム ゲー・エム・ベー・ハー シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102010359B (zh) * 2010-09-10 2013-01-23 北京阳光诺和药物研究有限公司 β晶型西洛多辛的制备方法
WO2012077138A1 (en) 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
PL2474529T3 (pl) * 2010-12-23 2014-10-31 Sandoz Ag Formy krystaliczne farmaceutycznej substancji czynnej
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) * 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
CN105142633A (zh) * 2013-03-26 2015-12-09 橘生药品工业株式会社 西洛多辛苦味被掩蔽的口服给药制剂
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
WO2015015512A2 (en) * 2013-07-29 2015-02-05 Ind-Swift Laboratories Limited Process for the preparation of silodosin and its gamma form
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
US9643921B2 (en) 2014-02-06 2017-05-09 Ube Industries, Ltd. Method for producing indoline compound
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR101733084B1 (ko) 2016-07-27 2017-05-08 (주)다산메디켐 실로도신의 결정형의 제조방법
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN107903201B (zh) * 2017-12-27 2020-09-25 浙江天宇药业股份有限公司 一种β晶型西洛多辛的制备方法
CN111410626B (zh) * 2019-01-04 2022-11-04 上海汇伦医药股份有限公司 赛洛多辛α-晶型的制备方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法
WO2020237643A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛α-晶型的制备方法
CN114601826A (zh) * 2022-03-31 2022-06-10 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330726A (ja) * 1994-06-01 1995-12-19 Kissei Pharmaceut Co Ltd インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
JP2000247998A (ja) * 1999-02-26 2000-09-12 Kissei Pharmaceut Co Ltd α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
ES2362788T3 (es) * 2004-10-27 2011-07-13 Kissei Pharmaceutical Co., Ltd. Compuesto de indolina y proceso para la producción del mismo.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330726A (ja) * 1994-06-01 1995-12-19 Kissei Pharmaceut Co Ltd インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
JP2000247998A (ja) * 1999-02-26 2000-09-12 Kissei Pharmaceut Co Ltd α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Also Published As

Publication number Publication date
MXPA05002549A (es) 2005-06-03
CA2496780A1 (en) 2004-03-18
ATE416159T1 (de) 2008-12-15
EP1541554A4 (en) 2006-11-08
CA2496780C (en) 2011-03-15
BR0314338A (pt) 2005-07-05
NO329855B1 (no) 2011-01-10
WO2004022538A1 (ja) 2004-03-18
HRP20050214A2 (en) 2006-05-31
EP1541554A1 (en) 2005-06-15
TW200407126A (en) 2004-05-16
TWI305148B (hr) 2009-01-11
NO2011011I1 (no) 2011-07-25
ZA200501884B (en) 2006-05-31
US20060142374A1 (en) 2006-06-29
KR100670592B1 (ko) 2007-01-17
EP1541554B1 (en) 2008-12-03
AU2003264385A1 (en) 2004-03-29
RU2347774C2 (ru) 2009-02-27
NZ538598A (en) 2007-08-31
HK1084396A1 (en) 2006-07-28
IS7785A (is) 2005-04-05
PL375701A1 (en) 2005-12-12
CN1694867A (zh) 2005-11-09
JP4532274B2 (ja) 2010-08-25
AU2003264385B2 (en) 2009-12-17
JPWO2004022538A1 (ja) 2005-12-22
CN1321111C (zh) 2007-06-13
DE60325074D1 (de) 2009-01-15
KR20050057181A (ko) 2005-06-16
NO20051709L (no) 2005-06-06
NO2011011I2 (hr) 2012-10-01
IS2640B (is) 2010-06-15
IL167168A (en) 2010-11-30
RU2005109930A (ru) 2006-01-20
ES2316858T3 (es) 2009-04-16
UA78854C2 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
HK1084396A1 (en) Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
HU229581B1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
IN2015DN01132A (hr)
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
CA2476800A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
WO2005044192A3 (en) Triazole compounds and uses related thereto
SE9901573D0 (sv) New compounds
MY121170A (en) Polymorphic salt of an anti-migrain drug.
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
SE9901572D0 (sv) New compounds
SE0201837D0 (sv) Chemical compounds
NO20013601L (no) Nye morfolinobenzamidsalter
SE0103272D0 (sv) Chemical compounds
AU2001260695A1 (en) Malto-oligosaccharide derivatives and use thereof
IL143873A0 (en) Dry skin remedies
NO20045223L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190809

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200819

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210830

Year of fee payment: 19

PBON Lapse due to non-payment of renewal fee

Effective date: 20220905